Please assess the completion status of the following clinical trial:

Trial Title: B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV-1 seropositive~2. Age \> 21 years~3. Receiving ATP \> 2 years as their only ART, with HIV-1 RNA \< 50 copies/mL at screening and all HIV-1 RNA tests \< 100 copies/mL in the past 18 months~4. No documented resistance mutations to the components of ATP~5. Any CD4 count, but no active AIDS-defining opportunistic infections or cancers~6. HBsAg+ permitted if plasma HBV DNA is unquantifiable and the patient does not have decompensated liver disease~Exclusion Criteria:~1. Pregnancy, breastfeeding or planned pregnancy in the next 2 years~2. Documented resistance to the components of ATP~3. Active AIDS-defining opportunistic infection or cancer~4. Cancer in past 3 years, except non melanoma skin cancer~5. Active psychotic disease or active depression that may interfere with study participation according investigator discretion~6. Any illness with a life expectancy less than 2 years~7. eGFR \< 50 mL/min~8. Urine protein/creatinine \> 40 mg/mmoL~9. Patients who the investigator feels are unlikely to commit to the study requirements for any reason~10. Prescription drug therapy for osteoporosis (calcium and/or vitamin D is allowed)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- B/F/TAF (Type: EXPERIMENTAL): B/F/TAF + Atripla Placebo~Each pill is taken once daily, (total of 2 tablets) The blinded treatment phase of this study will last for 52 weeks
- Atripla (Type: ACTIVE_COMPARATOR): Atripla + B/F/TAF Placebo~Each pill is taken once daily, (total of 2 tablets) The blinded treatment phase of this study will last for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).